Clinical Trial Update: A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK [Phase 2]

View source ↗

Summary

Phase II clinical study of LCB01-0371 evaluating efficacy, safety, and pharmacokinetics in pulmonary tuberculosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Drugs mentioned

• LCB01-0371

Snippet

Sponsor: LigaChem Biosciences, Inc. | Conditions: Pulmonary Tuberculosis | Phase 2 | Status: COMPLETED